Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
216 | 51214 | 32.7 | 76% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
6 | 4 | GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY | 1371034 |
216 | 3 | NON SMALL CELL LUNG CANCER//LUNG CANCER//THORAC SURG | 51214 |
337 | 2 | THORAC SURG//LUNG CANCER//RESPIRATORY SYSTEM | 17838 |
1102 | 2 | PACLITAXEL//TAXANES//EPOTHILONES | 9807 |
1422 | 2 | XRCC1//GEMCITABINE//ERCC1 | 7962 |
1612 | 2 | SMALL CELL LUNG CANCER//BOMBESIN//GASTRIN RELEASING PEPTIDE | 7087 |
1717 | 2 | GEFITINIB//EGFR MUTATION//MIDKINE | 6648 |
3290 | 2 | HAND FOOT SYNDROME//HYPERSENSITIVITY REACTION//RADIATION RECALL | 1872 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | NON SMALL CELL LUNG CANCER | authKW | 1093226 | 8% | 44% | 4223 |
2 | LUNG CANCER | authKW | 587373 | 8% | 23% | 4344 |
3 | THORAC SURG | address | 422342 | 7% | 19% | 3784 |
4 | ONCOLOGY | WoSSC | 375680 | 45% | 3% | 22801 |
5 | JOURNAL OF THORACIC ONCOLOGY | journal | 327772 | 2% | 46% | 1216 |
6 | PACLITAXEL | authKW | 287649 | 3% | 28% | 1725 |
7 | RESPIRATORY SYSTEM | WoSSC | 281780 | 20% | 5% | 10046 |
8 | SMALL CELL LUNG CANCER | authKW | 251551 | 2% | 47% | 911 |
9 | NSCLC | authKW | 248340 | 2% | 38% | 1110 |
10 | GEMCITABINE | authKW | 244733 | 2% | 32% | 1277 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 375680 | 45% | 3% | 22801 |
2 | Respiratory System | 281780 | 20% | 5% | 10046 |
3 | Radiology, Nuclear Medicine & Medical Imaging | 15678 | 8% | 1% | 4075 |
4 | Cardiac & Cardiovascular System | 11936 | 7% | 1% | 3710 |
5 | Surgery | 11067 | 10% | 1% | 5121 |
6 | Critical Care Medicine | 5623 | 2% | 1% | 1227 |
7 | Pharmacology & Pharmacy | 5105 | 8% | 0% | 4341 |
8 | Pathology | 3890 | 3% | 1% | 1624 |
9 | Medicine, General & Internal | 1020 | 4% | 0% | 1995 |
10 | Chemistry, Medicinal | 709 | 2% | 0% | 981 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | THORAC SURG | 422342 | 7% | 19% | 3784 |
2 | THORAC ONCOL | 173819 | 2% | 38% | 782 |
3 | MED ONCOL | 143697 | 7% | 7% | 3400 |
4 | ONCOL | 46225 | 5% | 4% | 2431 |
5 | GEN THORAC SURG | 44610 | 1% | 19% | 400 |
6 | THORAC ONCOL SERV | 35449 | 0% | 55% | 108 |
7 | MULTIDISCIPLINARY THORAC ONCOL PROGRAM | 34504 | 0% | 75% | 77 |
8 | GUANGDONG LUNG CANC | 34265 | 0% | 58% | 100 |
9 | LOWE THORAC ONCOL | 33678 | 0% | 57% | 100 |
10 | P MED | 31977 | 2% | 5% | 1059 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | LUNG CANCER | 506949 | 4% | 44% | 1944 |
2 | JOURNAL OF THORACIC ONCOLOGY | 327772 | 2% | 46% | 1216 |
3 | CLINICAL LUNG CANCER | 121778 | 1% | 52% | 395 |
4 | SEMINARS IN ONCOLOGY | 80812 | 2% | 16% | 847 |
5 | JOURNAL OF THORACIC DISEASE | 63766 | 1% | 24% | 453 |
6 | JOURNAL OF CLINICAL ONCOLOGY | 42862 | 2% | 7% | 1101 |
7 | ANNALS OF THORACIC SURGERY | 42032 | 2% | 6% | 1239 |
8 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 41018 | 1% | 10% | 721 |
9 | EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 39254 | 1% | 9% | 743 |
10 | ANNALS OF ONCOLOGY | 38888 | 1% | 9% | 744 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | NON SMALL CELL LUNG CANCER | 1093226 | 8% | 44% | 4223 | Search NON+SMALL+CELL+LUNG+CANCER | Search NON+SMALL+CELL+LUNG+CANCER |
2 | LUNG CANCER | 587373 | 8% | 23% | 4344 | Search LUNG+CANCER | Search LUNG+CANCER |
3 | PACLITAXEL | 287649 | 3% | 28% | 1725 | Search PACLITAXEL | Search PACLITAXEL |
4 | SMALL CELL LUNG CANCER | 251551 | 2% | 47% | 911 | Search SMALL+CELL+LUNG+CANCER | Search SMALL+CELL+LUNG+CANCER |
5 | NSCLC | 248340 | 2% | 38% | 1110 | Search NSCLC | Search NSCLC |
6 | GEMCITABINE | 244733 | 2% | 32% | 1277 | Search GEMCITABINE | Search GEMCITABINE |
7 | GEFITINIB | 232482 | 1% | 51% | 766 | Search GEFITINIB | Search GEFITINIB |
8 | VINORELBINE | 207839 | 1% | 61% | 574 | Search VINORELBINE | Search VINORELBINE |
9 | DOCETAXEL | 206288 | 2% | 31% | 1112 | Search DOCETAXEL | Search DOCETAXEL |
10 | ERLOTINIB | 204982 | 1% | 51% | 682 | Search ERLOTINIB | Search ERLOTINIB |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | TRAVIS, WD , BRAMBILLA, E , NOGUCHI, M , NICHOLSON, AG , GEISINGER, KR , YATABE, Y , RIELY, GJ , VAN SCHIL, PE , GARG, K , HUBER, RM , ET AL (2011) INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER/AMERICAN THORACIC SOCIETY/EUROPEAN RESPIRATORY SOCIETY INTERNATIONAL MULTIDISCIPLINARY CLASSIFICATION OF LUNG ADENOCARCINOMA.JOURNAL OF THORACIC ONCOLOGY. VOL. 6. ISSUE 2. P. 244 -285 | 300 | 75% | 1311 |
2 | DACIC, S , GIACCONE, G , JENKINS, RB , KWIATKOWSKI, DJ , SALDIVAR, JS , SQUIRE, J , THUNNISSEN, E , LADANYI, M , LINDEMAN, NI , CAGLE, PT , ET AL (2013) MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS FOR EGFR AND ALK TYROSINE KINASE INHIBITORS GUIDELINE FROM THE COLLEGE OF AMERICAN PATHOLOGISTS, INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, AND ASSOCIATION FOR MOLECULAR PATHOLOGY.JOURNAL OF THORACIC ONCOLOGY. VOL. 8. ISSUE 7. P. 823 -859 | 256 | 84% | 228 |
3 | LINDEMAN, NI , CAGLE, PT , BEASLEY, MB , CHITALE, DA , DACIC, S , GIACCONE, G , JENKINS, RB , KWIATKOWSKI, DJ , SALDIVAR, JS , SQUIRE, J , ET AL (2013) MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS FOR EGFR AND ALK TYROSINE KINASE INHIBITORS GUIDELINE FROM THE COLLEGE OF AMERICAN PATHOLOGISTS, INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, AND ASSOCIATION FOR MOLECULAR PATHOLOGY.JOURNAL OF MOLECULAR DIAGNOSTICS. VOL. 15. ISSUE 4. P. 415 -453 | 254 | 84% | 139 |
4 | LINDEMAN, NI , CAGLE, PT , BEASLEY, MB , CHITALE, DA , DACIC, S , GIACCONE, G , JENKINS, RB , KWIATKOWSKI, DJ , SALDIVAR, JS , SQUIRE, J , ET AL (2013) MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS FOR EGFR AND ALK TYROSINE KINASE INHIBITORS.ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. VOL. 137. ISSUE 6. P. 828 -860 | 252 | 84% | 138 |
5 | JENSEN, RT , BATTEY, JF , SPINDEL, ER , BENYA, RV , (2008) INTERNATIONAL UNION OF PHARMACOLOGY. LXVIII. MAMMALIAN BOMBESIN RECEPTORS: NOMENCLATURE, DISTRIBUTION, PHARMACOLOGY, SIGNALING, AND FUNCTIONS IN NORMAL AND DISEASE STATES.PHARMACOLOGICAL REVIEWS. VOL. 60. ISSUE 1. P. 1-42 | 340 | 76% | 215 |
6 | WANG, YF , SHI, QW , DONG, M , KIYOTA, H , GU, YC , CONG, B , (2011) NATURAL TAXANES: DEVELOPMENTS SINCE 1828.CHEMICAL REVIEWS. VOL. 111. ISSUE 12. P. 7652-7709 | 341 | 87% | 43 |
7 | CALLISTER, MEJ , BALDWIN, DR , AKRAM, AR , BARNARD, S , CANE, P , DRAFFAN, J , FRANKS, K , GLEESON, F , GRAHAM, R , MALHOTRA, P , ET AL (2015) BRITISH THORACIC SOCIETY GUIDELINES FOR THE INVESTIGATION AND MANAGEMENT OF PULMONARY NODULES.THORAX. VOL. 70. ISSUE . P. 1 -54 | 238 | 69% | 31 |
8 | STEWART, DJ , CHIRITESCU, G , DAHROUGE, S , BANERJEE, S , TOMIAK, EM , (2007) CHEMOTHERAPY DOSE - RESPONSE RELATIONSHIPS IN NON-SMALL CELL LUNG CANCER AND IMPLIED RESISTANCE MECHANISMS.CANCER TREATMENT REVIEWS. VOL. 33. ISSUE 2. P. 101-137 | 249 | 91% | 12 |
9 | AZZOLI, CG , BAKER, S , TEMIN, S , PAO, W , ALIFF, T , BRAHMER, J , JOHNSON, DH , LASKIN, JL , MASTERS, G , MILTON, D , ET AL (2009) AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE ON CHEMOTHERAPY FOR STAGE IV NON-SMALL-CELL LUNG CANCER.JOURNAL OF CLINICAL ONCOLOGY. VOL. 27. ISSUE 36. P. 6251-6266 | 129 | 86% | 415 |
10 | FENG, YZ , LIU, YL , HE, XF , WEI, W , SHEN, XL , XIE, DL , (2014) ASSOCIATION BETWEEN THE XRCC1 ARG194TRP POLYMORPHISM AND RISK OF CANCER: EVIDENCE FROM 201 CASE-CONTROL STUDIES.TUMOR BIOLOGY. VOL. 35. ISSUE 11. P. 10677 -10697 | 183 | 92% | 6 |
Classes with closest relation at Level 3 |